Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 3/20 | 0.40 |
| ▸ | TRPM8 | Q7Z2W7 | 4/20 | 0.38 |
| ▸ | TRPA1 | O75762 | 2/20 | 0.38 |
| ▸ | GABRA1 | P14867 | 3/20 | 0.34 |
| ▸ | GABRA5 | P31644 | 3/20 | 0.34 |
| ▸ | GABRB2 | P47870 | 3/20 | 0.34 |
| ▸ | GABRR1 | P24046 | 2/20 | 0.34 |
| ▸ | GABRA4 | P48169 | 1/20 | 0.34 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.32 |
| ▸ | ACE | P12821 | 1/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3270403 | 0.88 | EPHX1 (0.34) | EPHX1TRPM8TRPA1GABRA1GABRA5 | |
| SCHEMBL18629656 | 0.86 | MEN1 (0.36) | EPHX1TRPM8TRPA1GABRA1GABRA5 | |
| SCHEMBL10280048 | 0.86 | MEN1 (0.36) | EPHX1TRPM8TRPA1GABRA1GABRA5 | |
| SCHEMBL4706834 | 0.81 | — | — | |
| SCHEMBL14599126 | 0.81 | — | — | |
| SCHEMBL1904748 | 0.81 | — | — | |
| SCHEMBL17755867 | 0.79 | EPHX1 (0.38) | EPHX1TRPM8TRPA1ALOX5 | |
| Ammonia Solution, Strong SCHEMBL27687915 | 0.79 | — | — | |
| Hydrochloric Acid SCHEMBL8026838 | 0.79 | — | — | |
| SCHEMBL2232208 | 0.78 | DPP4 (0.41) | GABRA1GABRA5GABRB2GABRR1GABRA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108473518-B | Bisphosphonic acid compounds | 株式会社富士药品 | 2021-07-06 | — | — | CN | disclosed |
| WO-2020251957-A1 | PROSTAGLANDIN E2 RECEPTOR 4 ANTAGONISTS AND USES THEREOF | TEON THERAPEUTICS, INC. (US) | 2020-12-17 | — | — | WO | disclosed |
| US-10689408-B2 | Bisphosphonic acid compound | FUJIYAKUHIN CO., LTD. (JP) | 2020-06-23 | — | — | US | disclosed |
| US-20190167636-A1 | METHODS FOR TREATING PULMONARY EMPHYSEMA USING SUBSTITUTED 2-AZA-BICYCLO[2.2.1]HEPTANE-3-CARBOXYLIC ACID (BENZYL-CYANO-METHYL)-AMIDES INHIBITORS OF CATHEPSIN C | BOEHRINGER INGELHEIM INT (DE) | 2019-06-06 | — | — | US | disclosed |
| US-10238633-B2 | Methods for treating pulmonary emphysema using substituted 2-Aza-bicyclo[2.2.1]heptane-3-carboxylic acid (benzyl-cyano-methyl)-amides inhibitors of Cathepsin C | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2019-03-26 | — | — | US | disclosed |
| US-20190002482-A1 | NOVEL BISPHOSPHONIC ACID COMPOUND | FUJIYAKUHIN CO., LTD. (JP) | 2019-01-03 | — | — | US | disclosed |
| EP-3409679-A1 | NOVEL BISPHOSPHONIC ACID COMPOUND | Fuji Yakuhin Co., Ltd. (JP) | 2018-12-05 | — | — | EP | disclosed |
| CN-108473518-A | New double phosphinic acid compounds | 株式会社富士药品 | 2018-08-31 | — | — | CN | disclosed |
| US-20170266160-A1 | METHODS FOR TREATING PULMONARY EMPHYSEMA USING SUBSTITUTED 2-AZA-BICYCLO[2.2.1]HEPTANE-3-CARBOXYLIC ACID (BENZYL-CYANO-METHYL)-AMIDES INHIBITORS OF CATHEPSIN C | BOEHRINGER INGELHEIM INT (DE) | 2017-09-21 | — | — | US | disclosed |
| US-9713606-B2 | Methods for treating pulmonary emphysema using substituted 2-Aza-bicyclo[2.2.1]heptane-3-carboxylic acid (benzyl-cyano-methyl)-amides inhibitors of cathepsin C | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2017-07-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10238633-B2 | Methods for treating pulmonary emphysema using substituted 2-Aza-bicyclo[2.2.1]heptane-3-carboxylic acid (benzyl-cyano-methyl)-amides inhibitors of Cathepsin C | CTSC, CTSG, CTSZ | EPHX1 584/4885TRPM8 4220/4885TRPA1 4774/4885 |
| US-20190167636-A1 | METHODS FOR TREATING PULMONARY EMPHYSEMA USING SUBSTITUTED 2-AZA-BICYCLO[2.2.1]HEPTANE-3-CARBOXYLIC ACID (BENZYL-CYANO-METHYL)-AMIDES INHIBITORS OF CATHEPSIN C | CTSC, CTSG, CTSZ | EPHX1 584/4885TRPM8 4220/4885TRPA1 4774/4885 |
| US-10689408-B2 | Bisphosphonic acid compound | SOST, PTH1R, BMP2 | EPHX1 1992/4885TRPM8 1230/4885TRPA1 585/4885 |
| US-20170266160-A1 | METHODS FOR TREATING PULMONARY EMPHYSEMA USING SUBSTITUTED 2-AZA-BICYCLO[2.2.1]HEPTANE-3-CARBOXYLIC ACID (BENZYL-CYANO-METHYL)-AMIDES INHIBITORS OF CATHEPSIN C | CTSC, CTSG, CTSZ | EPHX1 584/4885TRPM8 4220/4885TRPA1 4774/4885 |
| US-20190002482-A1 | NOVEL BISPHOSPHONIC ACID COMPOUND | SOST, PTH1R, BMP2 | EPHX1 2353/4885TRPM8 1348/4885TRPA1 676/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.